Review Article

Improving Cell Engraftment in Cardiac Stem Cell Therapy

Xiaofei Li,1 Kenichi Tamama,2,3 Xiaoyun Xie,4 and Jianjun Guan1,5

1Department of Materials Science and Engineering, The Ohio State University, 2041 College Road, Columbus, OH 43210, USA
2Department of Pathology, University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA 15261, USA
3McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA
4Department of Gerontology, Tongji Hospital, Tongji University, Shanghai 200065, China
5Tongji Hospital, Tongji University, Shanghai 200065, China

Correspondence should be addressed to Jianjun Guan; guan.21@osu.edu

Received 21 April 2015; Revised 22 July 2015; Accepted 11 August 2015

Academic Editor: Toru Hosoda

Myocardial infarction (MI) affects millions of people worldwide. MI causes massive cardiac cell death and heart function decrease. However, heart tissue cannot effectively regenerate by itself. While stem cell therapy has been considered an effective approach for regeneration, the efficacy of cardiac stem cell therapy remains low due to inferior cell engraftment in the infarcted region. This is mainly a result of low cell retention in the tissue and poor cell survival under ischemic, immune rejection and inflammatory conditions. Various approaches have been explored to improve cell engraftment: increase of cell retention using biomaterials as cell carriers; augmentation of cell survival under ischemic conditions by preconditioning cells, genetic modification of cells, and controlled release of growth factors and oxygen; and enhancement of cell survival by protecting cells from excessive inflammation and immune surveillance. In this paper, we review current progress, advantages, disadvantages, and potential solutions of these approaches.

1. Introduction

Heart disease has a high rate of morbidity and mortality [1]. Myocardial infarction (MI) is a major heart disease that causes massive cardiac cell death and partial loss of heart function. The infarcted heart tissue cannot effectively regenerate by itself because adult cardiomyocytes are unable to proliferate, and cardiac stem cells spontaneously generate only a limited number of cardiomyocytes [2]. Heart function thus cannot be restored. Following MI, the left ventricular wall progressively becomes thinner, and heart function gradually decreases. This adverse remodeling process leads to heart failure [3]. Heart transplantation is the only solution for patients with end-stage heart failure, but the number of donors available for transplantation is extremely limited, and the recipients require long-term immune suppressants to prevent organ rejection. Stem cell therapy is an alternate strategy. It aims to regenerate the infarcted heart tissue and/or improve heart function.

2. Stem Cells for Cardiac Therapy

Multiple stem cell types have been tested in animal models and clinical trials for cardiac therapy. Some stem cell types are capable of differentiating into cardiomyocytes to regenerate the heart tissue, leading to the restoration of heart function. These cells include cardiac stem cells [4–8] and pluripotent stem cell-derived cardiovascular progenitor cells [9, 10]. Some stem cell types cannot differentiate into functional cardiomyocytes but provide paracrine effects to augment the survival of resident cardiac cells, vascularize infarcted heart tissue, modulate immune response, recruit endogenous stem cells, and facilitate beneficial remodeling [11–17], resulting in an overall improvement of heart function. These stem cells include bone marrow-derived stem cells [18–23], adipose-derived stem cells [24–27], and cardiosphere-derived cells (CDCs) [28–35].

In the majority of current animal studies and clinical trials, stem cells are injected directly into the infarcted
heart. However approximately 90% of cells are lost to the circulation, leaked, or squeezed out of the injection site [36]. For those cells retained in the infarcted tissue, most of them die within the first few weeks [37]. Overall, cell engraftment of current stem cell therapy is low, and its therapeutic efficacy is limited.

3. Major Causes of Low Cell Engraftment in Infarcted Hearts

As discussed above, the major causes of the low cell engraftment are inferior cell retention and survival in the infarcted heart tissue. The commonly used saline solution has very low viscosity and cannot efficiently hold the cells in tissue. Transplanted cell death is mainly a result of inadequate cell attachment to the host tissue, severe ischemia, and excessive inflammation. Anoikis is a form of programmed cell death of adherent cells induced by poor or weak interaction between cell and extracellular matrix (ECM) [38]. In normal heart tissue, adherent cells attach strongly to the surrounding ECM. In the infarcted tissue, however, the ECM does not allow strong cell attachment [39]. Moreover, the saline used for cell transplantation does not provide cells with a matrix for attachment. These events cause anoikis [40].

Another factor is oxygen tension in the tissue. After MI, an extremely low oxygen and nutrient ischemic environment exists in the infarcted region. Although hypoxia is considered necessary to preserve the stem cell properties [41], the harsh ischemic environment activates cell death pathways, resulting in death of the transplanted cells [42].

Following MI, acute inflammation ensues with recruitment of inflammatory cells (neutrophils and monocytes) into the infarcted heart tissue. These recruited inflammatory cells are engaged in production of various inflammatory cytokines and chemokines to recruit more inflammatory cells, secretion of various proteolytic enzymes and reactive oxygen species (ROS), and phagocytosis to remove dead cells and tissue debris [43–45]. Both ROS and proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), can compromise survival of transplanted cells.

4. Approaches to Improve Stem Cell Engraftment

To increase cell engraftment in infarcted hearts, improving both cell retention and survival is necessary. The former may be achieved by using viscous, injectable hydrogels as cell carriers since low viscosity saline cannot efficiently hold cells in tissue. An injectable hydrogel can be delivered into the infarcted hearts through a minimal invasive injection approach (Figure 1) [49]. Seeding cells into scaffolds and patching them onto the heart may also increase cell retention (Figure 1). Both injectable hydrogels and scaffolds can augment cell survival. They provide an environment for cell attachment, which is required for cell survival. They can also be modified to promote stem cell survival under ischemic and inflammatory conditions [50]. In addition, the hydrogels and scaffolds offer mechanical support to the infarcted tissue to improve cardiac function.

To address the issue of cell survival under ischemic conditions, approaches including ischemic preexposure of cells, genetic modulation of cells, and delivery of growth factors and oxygen to cells have been used. To promote cell survival under inflammatory conditions, biomaterials have been modified to prevent immune proteins and proinflammatory cytokines from penetrating inside to attack the encapsulated stem cells.

4.1. Using Biomaterials and Cell Adhesion Molecules for Stem Cell Delivery. Biomaterials used for stem cell transplantation should be biodegradable and biocompatible [51]. Specifically, they should have a controlled biodegradation rate, which ideally coincides with the rate of new tissue regeneration [52]. The degradation products should be nontoxic. The biomaterials should ideally mimic mechanical properties of the heart tissue, for example, stiffness. This will decrease the elevated wall stress to improve cardiac function [53]. Both natural and synthetic polymers have been employed for stem cell transplantation. Natural polymers are biologically derived materials. Some of them, like fibrin [49, 54], alginate [55–57], collagen [58, 59], Matrigel [60], hyaluronic acid [61], and chitosan [62], have been used to deliver stem cells into infarcted hearts.

Synthetic polymers are generated via chemical method to pursue desired properties and functions. The properties can be controlled by composition and chemistry. The capability of endowing synthetic polymers with functional groups and tunable properties are advantages of using these polymers for stem cell transplantation [63]. Commonly used synthetic polymers include polyesters, such as polyglycolide (PGA), polylactide (PLA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), and their copolymers [64]. These polymers are often used in the form of scaffold. PLGA scaffolds loaded with bFGF have been used to promote cardiac angiogenesis [65]. Porous PCL scaffolds have been used to deliver endothelial progenitor cells into heart tissue to promote vascularization [66].

Some synthetic polymers can be used in the form of hydrogel. For example, Li et al. generated thermosensitive hydrogels based on N-isopropylacrylamide (NIPAAm), acrylic acid (AAC), dimethyl-gamma-butyrolactone acrylate (DBA), and 2-hydroxyethyl methacrylate-poly(trimethylene carbonate) (HEMAPTMC) [46]. The hydrogels are injectable at room temperature and solidify at body temperature within 10 seconds. They can therefore quickly solidify to efficiently hold cells in the tissue. Interestingly, mesenchymal stem cells (MSCs) were able to proliferate inside (Figure 2). Other synthetic hydrogels developed for cardiac repair include poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) (PEO-PPO-PEO) [67], poly(D-lysine) (PDL) [68], and MPEG-PCL-MPEG [69, 70].

Biomaterials can be modified with cell adhesive molecules to improve cell attachment, thus decreasing anoikis-induced stem cell death during transplantation [71]. Cell adhesive molecules are often mixed with or conjugated
to the biomaterials. Karoubi et al. studied MSC survival in agarose with and without the addition of fibronectin and fibrinogen [72]. The results showed that cell survival was significantly increased after addition of fibronectin and fibrinogen. Similarly, fibrin glue remarkably improved cell survival in infarcted hearts [54]. Cooke et al. investigated cell adhesion on surfaces modified with several cell adhesive molecules, collagen I, collagen IV, fibronectin, and laminin, and found that cell attachment was increased [71]. Peptides YIGSR/IKVAV and RGD derived from laminin and fibronectin, respectively, have also been used to modify biomaterials to improve cell affinity [73].

4.2. Preexposure of Stem Cells for Enhanced Cell Survival. Preexposure of stem cells with ischemia or cytokines for cytoprotection is an alternate strategy to alleviate cell death. It enhances the cell tolerance to the harsh ischemic conditions. Murry et al. showed that cyclic exposure of stem cells to ischemia improved cell survival in ischemic myocardium [74]. Maulik et al. further demonstrated that ischemic preexposure allowed cells to adapt to ischemia, thus attenuating cell death under ischemia [75]. Grund et al. found that ischemically preexposed cells had reduced oxygen consumption [76]. In addition, ischemic preexposure enhanced cell secretion of growth factors [77, 78].

Cytokine preexposure can also improve cell survival [79–81]. MSCs pretreated with SDF-1α released antiapoptotic and angiogenic cytokines to improve cell survival and augment tissue angiogenesis [79]. Preexposure of endothelial progenitor cells with VEGF and bFGF enhanced cell paracrine effects, resulting in enhanced cell survival, angiogenesis, and reduced infarct size and left ventricle remodeling [80, 81]. Cells pretreated with IGF-1 showed cytoprotection effect both in vitro and in vivo [82, 83]. PI3K/Akt and MAPK/Erk1/2 pathways are responsible for the prosurvival effect.

4.3. Release of Growth Factors to Improve Cell Survival. High rates of both short-term and long-term cell survival are necessary for cardiac stem cell therapy. These may be achieved by using growth factors. Prosurvival growth factors allow for short-term cell survival, while angiogenic growth factors stimulate angiogenesis for long-term cell survival [84–86]. IGF-1 and HGF are two commonly used prosurvival growth factors. FGF [87], PDGF [88], and VEGF [89] are angiogenic growth factors used to promote angiogenesis in various tissues. bFGF also enhances cell survival under ischemic conditions [47]. In addition, specific growth factors can be used with prosurvival and angiogenic growth factors to promote stem cell differentiation into functional cells such as cardiomyocytes [90–92].

However, a concern for using growth factors in stem cell transplantation is that most of them have a relatively short half-life [93, 94]. Genetic modification of stem cells to promote the cells to secrete prosurvival and proangiogenic growth factors and sustained release of growth factors using biomaterials are commonly used approaches to address this concern.

Stem cells transfected with encoded genes of angiogenic growth factors like VEGF and FGF; and antiapoptotic factors like Akt and heme oxygenase-1, were able to secrete autocrine and paracrine growth factors [95, 96]. After transplanting these cells into infarcted hearts, cell survival, angiogenesis, and heart function were improved [97–99]. Matsumoto et al. transfected VEGF gene to MSCs and injected the modified cells into MI rat hearts [100]. High expression of VEGF was detected. This not only reduced cell death and increased capillary density, but also decreased the infarct size.

The growth factors are often encapsulated in biomaterials for controlled release [101–103]. Li et al. developed a bFGF release system based on a thermoresponse and degradable hydrogel [47]. bFGF can be gradually released from the hydrogel for more than 2 weeks. The bFGF releasing system significantly increased MSC survival under low oxygen and nutrient conditions (Figure 3). It is expected that transplantation of stem cells using this bFGF release system will augment cell survival in the infarcted hearts. The release system may also promote angiogenesis due to the angiogenic effect of bFGF.

Padin-Iruega et al. tethered IGF-1 to self-assembling peptide nanofibers and used them for delivery of cardiac progenitor cells (CPCs) into infarcted hearts [104]. The IGF-1 was found to continuously release from the nanofibers to the myocardium. The released IGF-1 not only augmented CPC
survival but also promoted cardiac differentiation, leading to enhanced cardiac regeneration.

4.4. Augmentation of Cell Survival by Releasing Oxygen to Transplanted Cells. Oxygen is critical for cell survival. The extremely low oxygen concentration in the infarcted heart results in significant cell death [105, 106]. Transplantation of stem cells with an oxygen release system is considered a feasible strategy to improve cell survival [107].

An oxygen release system can be generated using inorganic peroxide. Oh et al. developed a calcium peroxide-based oxygen release system by incorporating calcium peroxide into PLGA scaffold [108]. The system can continuously release oxygen for 10 days. The released oxygen enhanced cell survival under hypoxic conditions in vitro. However, this approach is not well suited for cardiac application since the $\text{Ca}^{2+}$ generated together with oxygen may lead to abnormal $\text{Ca}^{2+}$ transient in cardiomyocytes [109]. To avoid
the ion effect, organic molecules-based oxygen release systems, such as pyridine endoperoxide oxygen release system [110], hydrogen peroxide/poly(methyl methacrylate) microcapsule oxygen release system [111], and porphyrin-hemoprotein (rHSA(Fe-P-Glu)) oxygen release system [112], were developed and found to enhance cell survival. However, these oxygen release systems can release oxygen for less than 24 hours [108, 110–112].

To achieve longer term oxygen release, Abdi et al. encapsulated hydrogen peroxide into PLGA microspheres and obtained oxygen release for 7 days [113]. Li et al. encapsulated hydrogen peroxide/PVP complex in the PLGA microspheres and achieved sustained oxygen release at a relatively high oxygen level for 2 weeks (Figure 4) [48]. This oxygen release system significantly improved cell survival under hypoxic conditions in vitro. It has a great potential to augment cell survival in infarcted hearts for an extended period of time. Yet the concentration of released oxygen needs to be controlled so as not to overproduce ROS.

4.5. Modification of Biomaterials to Enhance Cell Survival under Immune Rejection and Inflammation Conditions

Immune rejection and excessive inflammation also decrease the survival rate of transplanted cells. Proinflammatory
cytokines like TNF-α and IL-1 induce excessive inflammation and create a noxious microenvironment, in addition to causing apoptosis of the cells [114]. Optimization of biomaterial properties and introduction of anti-inflammatory molecules into biomaterials may provide protection for the transplanted cells. By controlling pore size of the biomaterials, transplanted cells can be immunoisolated, leading to better cell survival of the transplanted cells [115–119]. However, small cytotoxic molecules such as TNF-α and IL-1β can still diffuse into the biomaterials [120, 121]. To address this issue, approaches like increasing degree of cross-linking and matrix concentration were used. However, these approaches may impede nutrient transport to cells. An alternate approach is to modify the biomaterials with anti-inflammatory molecules. For example, anti-TNF-peptide WP9QY (YCWSQYLCY) may be conjugated into hydrogel to prevent TNF from penetrating inside [122].

After MI, ROS content in the failing heart is upregulated [123], which can be cytotoxic against the transplanted cells. To decrease the cytotoxic effects of ROS, Hume and Anseth incorporated superoxide dismutase mimetic (SODm) into PEG hydrogel. This largely protected cells from oxidative stress damage and improved cell survival [124].

5. Conclusions and Prospects

Stem cell therapy is considered a potent and promising approach for cardiac therapy. However, the efficacy is limited as only a small percentage of transplanted cells engrafted in the infarcted tissue. Low cell retention and inferior cell survival are mainly responsible for the limited cell engraftment. Hydrogels and scaffolds can be utilized to improve cell retention. Injectable hydrogels may be more convenient for cell delivery than scaffolds as they can be delivered by a

minimally invasive injection approach. Injectable hydrogels increase cell retention because of their high viscosity. Yet, long gelation time may not allow the hydrogels to largely increase cell retention, as they may be squeezed out of heart tissue or washed into circulation before gelation. Some hydrogels require UV radiation, pH changing, or ion addition to solidify, which may cause potential harm to cells. Thermosensitive and biodegradable hydrogels that have a fast gelation rate (in seconds) may address this issue.

Different approaches have been explored to enhance cell survival in infarcted hearts. While they can improve cell survival to some extent, different types of stem cells may require dissimilar optimization approaches for preparation, activation, transplantation procedures, and maintenance in vivo. There are also disadvantages associated with these approaches. Ischemic preexposure may damage cells in the process, and the transplanted cells may not survive under ischemic conditions for a long enough period. Genetic modification of cells may raise safety concerns. Controlled release of growth factors and oxygen and immune protection appear to be more effective to promote cell survival. However, further studies on the long-term effect of these approaches on cell survival, functioning, and differentiation are needed.

From a clinical point of view, safety and efficacy are still paramount issues. More studies on animals are required in order to develop a reliable cell-biomaterial delivery system with long-term safety and efficacy. Biomaterial type, degradation product toxicity, dose, and timing must be well studied before clinical application.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
Acknowledgments

This work was supported by US National Science Foundation (1006734 and 1160122), American Heart Association (15GRNT25830058 and 13GRNT17150041), National Science Foundation of China (81471788), Institute for Materials Research Seed Grant at The Ohio State University, and Competitive Medical Research Fund from University of Pittsburgh Medical Center Health System.

References

[1] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e322, 2015.
[2] S. Etzioni, L. H. Kedes, R. A. Kloner, and J. Leor, “Myocardial regeneration: present and future trends,” American Journal of Cardiovascular Drugs, vol. 1, no. 4, pp. 233–244, 2001.
[3] J. N. Cohn, R. Ferrari, and N. Sharpe, “Cardiac remodeling—concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling,” Journal of the American College of Cardiology, vol. 35, no. 3, pp. 569–582, 2000.
[4] T. Hosoda, H. Zheng, M. Cabral-Da-Silva et al., “Human cardiac stem cell differentiation is regulated by a microrna mechanism,” Circulation, vol. 123, no. 12, pp. 1287–1296, 2011.
[5] A. R. Chugh, G. M. Beach, J. H. Loughran et al., “Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance,” Circulation, vol. 126, no. 11, pp. S54–S64, 2012.
[6] R. Bolli, X.-L. Tang, S. K. Sanganalmath et al., “Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy,” Circulation, vol. 128, no. 2, pp. 122–131, 2013.
[7] N. Latham, B. Ye, R. Jackson et al., “Human blood and cardiac stem cells synergize to enhance cardiac repair when cotransplanted into ischemic myocardium,” Circulation, vol. 128, supplement 1, no. 1, pp. S105–S112, 2013.
[8] A. R. Williams, K. E. Hatzistergos, B. Addicott et al., “Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction,” Circulation, vol. 127, no. 2, pp. 213–223, 2013.
[9] D. Spiter, M. K. Abramczuk, K. Buac et al., “A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells,” Nature Cell Biology, vol. 15, no. 9, pp. 1098–1106, 2013.
[10] A. Nsair, K. Schenke-Layland, B. van Handel et al., “Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells,” PLoS ONE, vol. 7, no. 10, Article ID e54603, 2012.
[11] J. S. Forrester, R. R. Makkar, and E. Marbán, “Long-term outcome of stem cell therapy for acute myocardial infarction: right results, wrong reasons,” Journal of the American College of Cardiology, vol. 53, no. 24, pp. 2270–2272, 2009.
[12] F. Wang and J. Guan, “Cellular cardiomypoplasty and cardiac tissue engineering for myocardial therapy,” Advanced Drug Delivery Reviews, vol. 62, no. 7-8, pp. 784–797, 2010.
[13] C. W. Don and C. E. Murry, “Improving survival and efficacy of pluripotent stem cell-derived cardiac grafts,” Journal of Cellular and Molecular Medicine, vol. 17, no. 11, pp. 1355–1362, 2013.
[14] Y. L. Tang, Y. J. Wang, L. J. Chen, Y. H. Pan, L. Zhang, and N. L. Weintrab, “Cardiac-derived stem cell-based therapy for heart failure: Progress and clinical applications,” Experimental Biology and Medicine, vol. 238, no. 3, pp. 294–300, 2013.
[15] J. C. Garbern and R. T. Lee, “Cardiac stem cell therapy and the promise of heart regeneration,” Cell Stem Cell, vol. 12, no. 6, pp. 689–698, 2013.
[16] M. R. Rosen, R. J. Myerburg, D. P. Francis, G. D. Cole, and E. Marbán, “Translating stem cell research to cardiac disease therapeutics: pitfalls and prospects for improvement,” Journal of the American College of Cardiology, vol. 64, no. 9, pp. 922–937, 2014.
[17] J. H. van Berlo and J. D. Molkentin, “An emerging consensus on cardiac regeneration,” Nature Medicine, vol. 20, no. 12, pp. 1386–1393, 2014.
[18] F. Wang and J. Guan, “Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy,” Advanced Drug Delivery Reviews, vol. 62, no. 7-8, pp. 784–797, 2010.
[19] R. R. Ripa, M. Haack-Sørensen, Y. Wang et al., “Bone marrow-derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial,” Circulation, vol. 116, no. 11, pp. 1128–1135, 2005.
[20] M. Gnecci, H. He, N. Noiseux et al., “Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement,” The FASEB Journal, vol. 20, no. 6, pp. 661–669, 2006.
[21] J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009.
[22] J. H. Traverse, D. H. McKenna, K. Harvey et al., “Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction,” American Heart Journal, vol. 160, no. 3, pp. 428–434, 2010.
[23] J. M. Duran, C. A. Makarewich, T. E. Sharp et al., “Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms,” Circulation Research, vol. 113, no. 5, pp. 539–552, 2013.
[24] M. Mazo, V. Planat-Bénard, G. Abizanda et al., “Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction,” European Journal of Heart Failure, vol. 10, no. 5, pp. 454–462, 2008.
[25] M. Mazo, S. Hernández, J. J. Gavira et al., “Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction,” Cell Transplantation, vol. 21, no. 12, pp. 2723–2733, 2012.
[26] E. K. Shevchenko, P. I. Makarewich, Z. I. Tsokolaeva et al., “Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle,” Journal of Translational Medicine, vol. 11, no. 1, article 138, 2013.
[27] M. Rigol, N. Solanes, S. Roura et al., “Allogeneic adipose stem cells improve cardiac function in a rat model of dilated cardiomyopathy,” Circulation, vol. 116, no. 8, pp. 1128–1135, 2005.
[29] D. R. Davis, Y. Zhang, R. R. Smith et al., “Validation of the cardiomyocyte-derived cells in porcine ischemic cardiomyopathy,” *Circulation*, vol. 120, no. 12, pp. 1075–1083, 2009.

[30] P. V. Johnston, T. Sasano, K. Mills et al., “Engraftment, differentiation, and functional benefits of autologous cardiomyocyte-derived cells in porcine ischemic cardiomyopathy,” *Circulation*, vol. 120, no. 12, pp. 1075–1083, 2009.

[31] I. Chimenti, R. R. Smith, T.-S. Li et al., “Relative roles of direct regeneration versus paracrine effects of human cardiomyocyte-derived cells transplanted into infarcted mice,” *Circulation Research*, vol. 106, no. 5, pp. 971–980, 2010.

[32] R. Mishra, K. Vijayan, E. J. Colletti et al., “Characterization and functionality of cardiac progenitor cells in congenital heart patients,” *Circulation*, vol. 123, no. 4, pp. 364–373, 2011.

[33] T.-S. Li, K. Cheng, K. Malliaras et al., “Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiomyocyte-derived cells,” *Journal of the American College of Cardiology*, vol. 59, no. 10, pp. 942–953, 2012.

[34] H. Maxeiner, S. Mufﬁ, N. Krebsbriele et al., “Interleukin-6 contributes to the paracrine effects of cardiomyocytes cultured from human, murine and rat hearts,” *Journal of Cellular Physiology*, vol. 229, no. 11, pp. 1681–1689, 2014.

[35] Y. Xie, A. Ibrahim, K. Cheng et al., “Importance of cell–cell contact in the therapeutic beneﬁts of cardiomyocyte-derived cells,” *Stem Cells*, vol. 32, no. 9, pp. 2397–2406, 2014.

[36] J. Leor, S. Aboulafia-Etzion, A. Dar et al., “Bioengineered cardiomyocytes: a new approach to repair the infarcted myocardium?” *Circulation*, vol. 102, no. 19, pp. III56–III61, 2000.

[37] H. Reinecke and C. E. Murry, “Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology,” *Journal of Molecular and Cellular Cardiology*, vol. 34, no. 3, pp. 251–253, 2002.

[38] S. M. Frisch and R. A. Scroton, “Anoikis mechanisms,” *Current Opinion in Cell Biology*, vol. 13, no. 5, pp. 555–562, 2001.

[39] K. Imanaka-Yoshida, M. Hiroe, and T. Yoshida, “Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling,” *Histology and Histopathology*, vol. 19, no. 2, pp. 517–525, 2004.

[40] S. M. Frisch and H. Francis, “Disruption of epithelial cell–matrix interactions induces apoptosis,” *Journal of Cell Biology*, vol. 124, no. 4, pp. 619–626, 1994.

[41] M. Csete, “Oxygen in the cultivation of stem cells,” *Annals of the New York Academy of Sciences*, vol. 1049, pp. 1–9, 2005.

[42] H. K. Haider and M. Ashraf, “Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation,” *Journal of Molecular and Cellular Cardiology*, vol. 45, no. 4, pp. 554–566, 2008.

[43] J. L. Mehta, W. W. Nichols, and P. Mehta, “Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion,” *Journal of the American College of Cardiology*, vol. 11, no. 6, pp. 1309–1316, 1988.

[44] M. Nahrendorf, F. K. Swirski, E. Aikawa et al., “The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions,” *The Journal of Experimental Medicine*, vol. 204, no. 12, pp. 3037–3047, 2007.

[45] M. Nahrendorf, S. Frantz, F. K. Swirski et al., “Imaging systemic inflammatory networks in ischemic heart disease,” *Journal of the American College of Cardiology*, vol. 65, no. 15, pp. 1583–1591, 2015.

[46] Z. Li, F. Wang, S. Roy, C. K. Sen, and J. Guan, “Injectable, highly ﬂexible, and thermosensitive hydrogels capable of delivering superoxide dismutase,” *Biomacromolecules*, vol. 10, no. 12, pp. 3306–3316, 2009.

[47] Z. Li, X. Guo, and J. Guan, “A thermosensitive hydrogel capable of releasing bFGF for enhanced differentiation of mesenchymal stem cell into cardiomyocyte-like cells under ischemic conditions,” *Biomacromolecules*, vol. 13, no. 6, pp. 1956–1964, 2012.

[48] Z. Li, X. Guo, and J. Guan, “An oxygen release system to augment cardiac progenitor cell survival and differentiation under hypoxic condition,” *Biomaterials*, vol. 33, no. 25, pp. 5914–5923, 2012.

[49] K. L. Christman and R. J. Lee, “Biomaterials for the treatment of myocardial infarction,” *Journal of the American College of Cardiology*, vol. 48, no. 5, pp. 907–913, 2006.

[50] M. S. Shoichet, “Polymer scaffolds for biomaterials applications,” *Macromolecules*, vol. 43, no. 2, pp. 581–591, 2009.

[51] B. L. Seal, T. C. Otero, and A. Panitch, “Polymeric biomaterials for tissue and organ regeneration,” *Mater. Sci. & Eng. R: Reports*, vol. 34, no. 4-5, pp. 147–230, 2001.

[52] H. Shin, S. Jo, and A. G. Mikos, “Biomimetic materials for tissue engineering,” *Biomaterials*, vol. 24, no. 24, pp. 4353–4364, 2003.

[53] K. L. Christman, H. H. Fok, R. E. Sievers, Q. Fang, and R. J. Lee, “Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction,” *Tissue Engineering*, vol. 10, no. 3-4, pp. 403–409, 2004.

[54] K. L. Christman, A. J. Vardanian, Q. Fang, R. E. Sievers, H. H. Fok, and R. J. Lee, “Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovascularization formation in ischemic myocardium,” *Journal of the American College of Cardiology*, vol. 44, no. 3, pp. 654–660, 2004.

[55] N. Landa, L. Miller, M. S. Feinberg et al., “Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat,” *Circulation*, vol. 117, no. 11, pp. 1388–1396, 2008.

[56] R. G. Gomez-Mauricio, A. Acarregui, F. M. Sánchez-Margallo et al., “A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model,” *European Journal of Pharmacetics and Biopharmaceutics*, vol. 84, no. 1, pp. 29–39, 2013.

[57] E. T. Roche, C. L. Hastings, S. A. Lewin et al., “Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart,” *Biomaterials*, vol. 35, no. 25, pp. 6850–6858, 2014.

[58] W. Dai, L. E. Wold, J. S. Dow, and R. A. Kloner, “Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction,” *Journal of the American College of Cardiology*, vol. 46, no. 4, pp. 714–719, 2005.

[59] E. J. Suvoronen, J. P. Veinot, N. Song et al., “Tissue-engineered injectable collagen-based matrices for improved cell delivery and vasculization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood,” *Circulation*, vol. 114, supplement, no. 1, pp. I38–I44, 2006.

[60] C. Xu, M. S. Inokuma, J. Denham et al., “Feeder-free growth of undifferentiated human embryonic stem cells,” *Nature Biotechnology*, vol. 19, no. 10, pp. 971–974, 2001.

[61] C. Y. Chang, A. T. Chan, P. A. Armstrong et al., “Hyaluronic acid-human blood hydrogels for stem cell transplantation,” *Biomaterials*, vol. 33, no. 32, pp. 8026–8033, 2012.
[62] M. Ishihara, K. Nakanishi, K. Ono et al., “Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing process,” *Biomaterials*, vol. 23, no. 3, pp. 833–840, 2002.

[63] N. Zhang and D. H. Kohn, “Using polymeric materials to control stem cell behavior for tissue regeneration,” *Birth Defects Research, Part C—Embryo Today: Reviews*, vol. 96, no. 1, pp. 63–81, 2012.

[64] R. C. Thomson, M. C. Wake, M. J. Yaszemski et al., “Biodegradable polymer scaffolds to regenerate organs,” in *Biopolymers II*, N. Peppas and R. Langer, Eds., pp. 245–274, Springer, Berlin, Germany, 1995.

[65] Y. Wang, X.-C. Liu, J. Zhao et al., “Degradable PLGA scaffolds with basic fibroblast growth factor: experimental studies in myocardial revascularization,” *Texas Heart Institute Journal*, vol. 36, no. 2, pp. 89–97, 2009.

[66] S. Singh, B. M. Wu, and J. C. Y. Dunn, “Accelerating vascularization in polycaprolactone scaffolds by endothelial progenitor cells,” *Tissue Engineering Part A*, vol. 17, no. 13–14, pp. 1819–1830, 2011.

[67] P. Bawa, V. Pillay, Y. E. Choonaar, and L. C. D. Toit, “Stimuli-responsive polymers and their applications in drug delivery,” *Biomedical Materials*, vol. 4, no. 2, Article ID 022001, 2009.

[68] K. E. Crompton, J. D. Goud, R. V. Bellamkonda et al., “Polylysine-functionalised thermo-responsive chitosan hydrogel for neural tissue engineering,” *Biomaterials*, vol. 28, no. 3, pp. 441–449, 2007.

[69] X.-J. Jiang, T. Wang, X.-Y. Li et al., “Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction,” *Journal of Biomedical Materials Research A*, vol. 90, no. 2, pp. 472–477, 2009.

[70] H. Tseng, D. S. Puperi, E. J. Kim et al., “Anisotropic poly(ethylene glycol)/polycaprolactone hydrogel–fiber composites for heart valve tissue engineering,” *Tissue Engineering Part A*, vol. 20, no. 19–20, pp. 2634–2645, 2014.

[71] M. J. Cooke, S. R. Phillips, D. S. H. Shah, D. Athey, J. H. Lakey, and S. A. Przyborski, “Enhanced cell attachment using a novel cell culture surface presenting functional domains from extracellular matrix proteins,” *Cytootechnology*, vol. 56, no. 2, pp. 71–79, 2008.

[72] G. Karoubi, M. L. Ormiston, D. J. Stewart, and D. W. Courtman, “Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells,” *Biomaterials*, vol. 30, no. 29, pp. 5445–5459, 2009.

[73] L. Jongpaiboonkit, W. J. King, and W. L. Murphy, “Screening for 3D environments that support human mesenchymal stem cell viability using hydrogel arrays,” *Tissue Engineering Part A*, vol. 15, no. 2, pp. 343–353, 2009.

[74] C. E. Murry, R. B. Jennings, and K. A. Reimer, “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium,” *Circulation*, vol. 74, no. 5, pp. 1124–1136, 1986.

[75] N. Maulik, T. Yoshida, R. M. Engelman et al., “Ischemic preconditioning attenuates apoptotic cell death associated with ischemia/reperfusion,” *Molecular and Cellular Biochemistry*, vol. 186, no. 1–2, pp. 139–145, 1998.

[76] F. Grund, H. T. Sommerschild, K. A. Kirkeboen, and A. Illebekk, “Preconditioning with ischaemia reduces both myocardial oxygen consumption and infarct size in a graded pattern,” *Journal of Molecular and Cellular Cardiology*, vol. 29, no. 11, pp. 3067–3079, 1997.

[77] M. Li, H. Nishimura, A. Iwakura et al., “Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via ‘imported’ nitric oxide synthase activity,” *Circulation*, vol. III, no. 9, pp. 1114–1120, 2005.

[78] S. Addya, K. Shiroto, T. Turoczi et al., “Ischemic preconditioning-mediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice,” *Journal of Molecular and Cellular Cardiology*, vol. 38, no. 2, pp. 345–351, 2005.

[79] S. Vandervelde, M. J. A. van Luyk, R. A. Tio, and M. C. Harmsen, “Signaling factors in stem cell-mediated repair of infarcted myocardium,” *Journal of Molecular and Cellular Cardiology*, vol. 39, no. 2, pp. 363–376, 2005.

[80] S. Shintani, K. Kusano, M. Ii et al., “Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI,” *Nature Clinical Practice Cardiovascular Medicine*, vol. 3, supplement 1, pp. S123–S128, 2006.

[81] Z. Pasha, Y. Wang, R. Sheikh, D. Zhang, T. Zhao, and M. Ashraf, “Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium,” *Cardiovascular Research*, vol. 77, no. 1, pp. 134–142, 2008.

[82] M. Párrizas, A. R. Saltiel, and D. LeRoith, “Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways,” *The Journal of Biological Chemistry*, vol. 272, no. 1, pp. 154–161, 1997.

[83] S. Humbert, E. A. Bryson, F. P. Cordelières et al., “The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt,” *Developmental Cell*, vol. 2, no. 6, pp. 831–837, 2002.

[84] J. E. Nör, J. Christensen, D. J. Mooney, and P. J. Polverini, “Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression,” *The American Journal of Pathology*, vol. 154, no. 2, pp. 375–384, 1999.

[85] T. Deuse, C. Peter, P. W. M. Fedak et al., “Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction,” *Circulation*, vol. 120, no. 1, pp. S247–S254, 2009.

[86] T.-J. Lee, S. H. Bhang, H. S. Yang et al., “Enhancement of long-term angiogenic efficacy of adipose stem cells by delivery of FGF2,” *Microvascular Research*, vol. 84, no. 1, pp. 1–8, 2012.

[87] F. Ma, Z. Xiao, B. Chen et al., “Accelerating proliferation of neural stem/progenitor cells in collagen sponges immobilized with engineered basic fibroblast growth factor for nervous system tissue engineering,” *Biomacromolecules*, vol. 15, no. 3, pp. 1062–1068, 2014.

[88] Y. Chen, H. Xu, J. Liu, C. Zhang, A. Leutz, and X. Mo, “The c-Myb functions as a downstream target of PDGF-mediated survival signal in vascular smooth muscle cells,” *Biochemical and Biophysical Research Communications*, vol. 360, no. 2, pp. 433–436, 2007.

[89] H. K. Haider, L. Ye, S. Jiang et al., “Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor,” *Journal of Molecular Medicine*, vol. 82, no. 8, pp. 539–549, 2004.

[90] K.-C. Choi, D.-S. Yoo, K.-S. Cho, P.-W. Huh, D.-S. Kim, and T.-J. Lee, S. H. Bhang, H. S. Yang et al., “Enhancement of long-term angiogenic efficacy of adipose stem cells by delivery of FGF2,” *Microvascular Research*, vol. 84, no. 1, pp. 1–8, 2012.

[91] A. Minato, H. Ise, M. Goto, and T. Akaike, “Cardiac differentiation of embryonic stem cells by substrate immobilization of insulin-like growth factor binding protein 4 with elastin-like polypeptides,” *Biomaterials*, vol. 33, no. 2, pp. 515–523, 2012.
myocardial infarction,” Free Radical Research, vol. 43, no. 1, pp. 37–46, 2009.

[124] P. S. Hume and K. S. Anseth, “Polymerizable superoxide dismutase mimetic protects cells encapsulated in poly(ethylene glycol) hydrogels from reactive oxygen species-mediated damage,” Journal of Biomedical Materials Research - Part A, vol. 99, no. 1, pp. 29–37, 2011.